Last 48 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
EV/EBITDA has compressed 44.0% YoY to 5.1x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 39.56 | — | 0.12 | — | 0.10 | — | 0.44 | 0.12 | 0.11 | — | 0.11 | — | 0.14 |
| — | — | -73.1% | — | -8.5% | — | +312.0% | — | -21.5% | — | +4.0% | — | +32.3% | |
| P/S Ratio | 1.65 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | +16.3% | +12.3% | +6.6% | +30.3% | +7.7% | -9.9% | -16.1% | -26.7% | -25.5% | -8.9% | +14.7% | +3.5% | |
| P/B Ratio | 1.04 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | +9.3% | +15.5% | -2.1% | +35.6% | +13.2% | -15.7% | -3.4% | -25.8% | -28.4% | -15.4% | +13.4% | +2.8% | |
| P/FCF | 9.77 | — | 0.04 | 0.04 | 0.09 | 0.07 | 0.03 | 0.05 | 0.09 | 0.05 | 0.16 | 0.09 | — |
| — | — | +27.0% | -28.2% | -4.0% | +45.7% | -81.0% | -47.4% | — | — | +336.3% | +67.1% | — | |
| EV / EBITDA | 9.13 | 5.09 | 2.74 | 3.66 | 2.87 | 9.09 | 4.32 | 2.81 | 3.29 | 11.89 | 3.79 | 5.77 | 3.29 |
| — | -44.0% | -36.6% | +30.0% | -12.7% | -23.5% | +14.1% | -51.3% | -0.1% | +204.7% | +34.3% | +58.1% | +1.7% | |
| EV / EBIT | 21.30 | 22.94 | 4.05 | 9.01 | 4.08 | — | 181.26 | 5.64 | 6.01 | 7.10 | 15.80 | — | 5.76 |
| — | — | -97.8% | +59.7% | -32.1% | — | +1047.4% | — | +4.4% | -72.3% | +223.5% | — | +21.4% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Takeda Pharmaceutical Company Limited's operating margin was 4.3% in Q4 2025, down 11.7 pp QoQ and up 11.4 pp YoY. The trailing four-quarter average of 10.8% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 23.4% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 51.1% | 48.8% | 54.4% | 65.8% | 65.2% | 63.7% | 63.6% | 66.5% | 68.0% | 63.1% | 65.8% | 67.1% | 69.7% |
| — | -23.4% | -14.4% | -0.9% | -4.0% | +0.9% | -3.5% | -0.9% | -2.4% | -6.6% | -5.1% | -3.5% | -0.3% | |
| Operating Margin | 12.0% | 4.3% | 16.0% | 6.2% | 16.7% | -7.1% | 5.9% | 15.7% | 13.8% | -1.0% | 9.4% | -4.7% | 15.9% |
| — | +160.0% | +173.4% | -60.4% | +21.1% | -642.0% | -38.0% | +431.2% | -13.5% | -110.3% | -29.6% | -145.4% | +2.9% | |
| Net Margin | 4.3% | -2.2% | 8.7% | -1.1% | 11.2% | -9.8% | 2.1% | 7.8% | 7.9% | -0.3% | 9.5% | -4.6% | 8.4% |
| — | +77.3% | +318.3% | -113.6% | +42.4% | -3311.1% | -78.1% | +270.0% | -6.6% | -108.8% | -12.4% | -174.7% | -21.8% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 2.8% | -0.3% | 1.4% | -0.2% | 1.8% | -1.4% | 0.3% | 1.3% | 1.3% | -0.0% | 1.5% | -0.7% | 1.3% |
| — | +77.7% | +330.3% | -113.5% | +42.5% | -3236.0% | -78.3% | +282.2% | -6.2% | -108.7% | -17.2% | -172.4% | -23.1% | |
| ROA | 1.4% | -0.2% | 0.7% | -0.1% | 0.9% | -0.7% | 0.2% | 0.6% | 0.6% | -0.0% | 0.7% | -0.3% | 0.6% |
| — | +77.2% | +340.4% | -113.9% | +44.7% | -3313.1% | -77.9% | +284.6% | -2.3% | -109.1% | -14.3% | -175.1% | -19.3% | |
| ROIC | 3.7% | 0.3% | 1.3% | 0.5% | 1.3% | -0.5% | 0.4% | 1.2% | 1.0% | -0.1% | 0.7% | -0.3% | 1.2% |
| — | +160.5% | +189.0% | -60.1% | +21.3% | -642.2% | -37.1% | +460.7% | -11.9% | -110.0% | -35.3% | -143.4% | +1.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Takeda Pharmaceutical Company Limited's Debt/EBITDA ratio is 22.9x, up from 12.5x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 26.5% YoY to 1.27x, strengthening the short-term liquidity position. Debt/Equity has declined for 4 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.63 | 0.63 | 0.63 | 0.65 | 0.66 | 0.65 | 0.65 | 0.73 | 0.70 | 0.67 | 0.69 | 0.66 | 0.69 |
| — | -3.5% | -2.7% | -10.7% | -6.6% | -2.2% | -5.7% | +10.3% | +2.5% | -3.4% | -0.3% | -6.2% | -5.9% | |
| Debt / EBITDA | 3.67 | 22.87 | 12.51 | 16.94 | 12.30 | 39.31 | 19.06 | 13.41 | 15.29 | 52.01 | 15.97 | 24.51 | 13.96 |
| — | -41.8% | -34.4% | +26.4% | -19.5% | -24.4% | +19.3% | -45.3% | +9.5% | +196.7% | +20.7% | +40.9% | -6.3% | |
| Current Ratio | 1.27 | 1.27 | 1.19 | 1.36 | 1.16 | 1.01 | 1.31 | 1.28 | 1.26 | 1.11 | 1.06 | 1.04 | 0.99 |
| — | +26.5% | -9.1% | +6.7% | -8.1% | -9.1% | +23.4% | +23.0% | +27.6% | +14.5% | -8.3% | -9.4% | -16.0% | |
| Quick Ratio | 0.70 | 0.70 | 0.65 | 0.76 | 0.59 | 0.52 | 0.72 | 0.77 | 0.74 | 0.58 | 0.55 | 0.55 | 0.56 |
| — | +34.0% | -8.9% | -2.1% | -21.0% | -10.8% | +30.3% | +40.3% | +33.8% | +2.5% | -26.0% | -26.4% | -25.8% | |
| Interest Coverage | 1.51 | 1.07 | 2.08 | 1.34 | 2.41 | -25.74 | 29.19 | 2.74 | 3.29 | 490.96 | 1.05 | -94.57 | 3.27 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Deep dive into TAK consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TAK stock.
Takeda Pharmaceutical Company Limited's current P/E is 39.6x. The average P/E over the last 2 quarters is 0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Takeda Pharmaceutical Company Limited's current operating margin is 12.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Takeda Pharmaceutical Company Limited's business trajectory between earnings reports.